Under various brand names such as Epitol, Carbatrol, Tegretol, and Tegretol XR, carbamazepine drugs are used for the treatment of a number of diseases such as borderline personality disorder, bipolar disorder, cyclothymic disorder, occipital neuralgia, peripheral neuropathy, cluster-tic syndrome, dystonia, epilepsy, diabetic peripheral neuropathy, reflex sympathetic dystrophy syndrome, vulvodynia, schizoaffective disorder, and trigeminal neuralgia. In October 2016, the Food and Drug Administration (FDA) approved carnexiv for the commercial use in the U.S., aiming to serve adult patients who are unable to take oral carbamazepine due to conditions such as gegneralized tonic-clonic seizures, partial seizures with complex symptomatology, and toehr mixed seizure patterns. Consequently, the demand in the global carbamazepine market is expected to expand at a healthy growth rate during the forecast period of 2017 to 2025. On the other hand, as is the case with oral carbamazepine products, the risk of severe dermatologic reactions during treatment processes with Carnexiv, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) as well as the possibilities of agranulocytosis and aplastic anemia. These factors are expected to hinder the growth rate of the carbamazepine market.
This report on the global carbamazepine market has been prepared to serve as a reliable business document for stakeholders of the market such as pharmaceutical companies, suppliers and distributors, and government agencies. All the important factors that are anticipated to increase or decrease the demand in the carbamazepine market have been comprehensively analyzed, and their final impacts have been estimated. The report also profiles some of the leading companies operating in this market in order to present a picture of the competitive landscape in its current scenario, and estimates the future until 2025. The report also takes stock of all the recent developments pertaining to carbamazepine market in order to complete a thorough study.
Carbamazepine sold under the brand names of Carbatrol, Epitol, Tegretol, Equetro, and TEGretol-XR., is a drug used primarily for the treatment of epilepsy and neuropathic pain. It is also used for schizophrenia as an alternate line of treatment as well as for bipolar disorder. The increasing demand for carbamazepine for the treatment of various types of seizures and bipolar disorders is expected to drive the global carbamazepine market in the next few years.
Carbamazepine is a white or yellowish-white crystalline powder, which is almost odorless. Carbamazepine is tasteless or has a slightly bitter taste. Carbamazepine are available as chewable tablet, suspension, tablet, extended release tablet, and extended release capsule.
Carbamazepine is suitable for the treatment of status epilepticus. Moreover, carbamazepine is utilized in the treatment of trigeminal neuralgia. Carbamazepine is utilized for the pain relief of idiopathic trigeminal and trigeminal neuralgia due to multiple sclerosis and also for the pain relief of idiopathic glossopharyngeal neuralgia. However, carbamazepine is not a simple analgesic and is not suitable to be used for trivial facial pain or headache. Moreover, carbamazepine is used for the treatment of mania and for maintaining the treatment of bipolar affective disorders or to prevent recurrence. However, carbamazepine is not effective in treating absence seizures, myoclonic seizures, and atonic seizures. Also, carbamazepine is not suitable for treating status epilepticus.
The report presents a detailed assessment of the market dynamics, growth trends, and opportunities that will impact the progression of the global carbamazepine market between 2017 and 2025. The report has been collated using primary and secondary research methodologies to present an exact case of this market. The report is focused on presenting a granular view of the various market segments along with the factors influencing them.
The report discuss the vendor landscape of the global carbamazepine market at length. This includes a competitive profile of the key vendors pertaining to their attributes of product specification and portfolio, financial standing, and recent developments. It also includes an analysis of the indices of strengths, weakness, opportunities, and threats of these vendors during the forecast period. Finally, the report includes comments and recommendations from industry experts for new and existing players.
The FDA has approved the medical use of carbamazepine for epilepsy, manic episodes of bipolar disorders, and trigeminal neuralgia. A controlled release formulation about carbamazepine was available by the FDA as of 2014, which provides tentative evidence regarding fewer side effects of the drug.
The dynamic growth of the epilepsy market with the increasing number of cases in the mid-teen age group is presenting lucrative growth opportunities to the carbamazepine market. For instance, in the U.S., the use of newer therapies for epilepsy and bipolar depression has witnessed a fourfold increase. The increasing number of individuals suffering from alcohol withdrawal disorders, central partial diabetes insipidus or water diabetes, and psychotic disorders is also driving the carbamazepine market.
Some of the leading players in the carbamazepine market are Novartis AG, Jubilant Pharma, Jiangsu Tohope, Shanghai Modern Hasen, Zhejiang Jiuzhou, and Jinan Jinda.